Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancerL Gianni, P Dombernowsky, G Sledge, et al.Cytometry|January 1, 1984
Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumorsO S Frankfurt, H K Slocum, Y M Rustum, et al.Journal of the National Cancer Institute. Monographs|January 1, 1993
Clinical development of TaxolS G Arbuck, M C Christian, J S Fisherman, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five daysP J Creaven, D E Brenner, J W Cowens, et al.Pharmacology & Therapeutics|August 24, 1999
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic targetE A Sausville, D Zaharevitz, R Gussio, et al.Cancer Chemotherapy and Pharmacology|September 28, 1998
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical modelsE A Sausville, R D Lush, D Headlee, et al.Journal of the National Cancer Institute|February 3, 2000
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaP Therasse, S G Arbuck, E A Eisenhauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinomaJ L Grem, E Jordan, M E Robson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B StudyP J O'Dwyer, J Manola, F H Valone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz, D Headlee, S F Stinson, et al.Pageof 7